Seagen Inc

NASDAQ:SGEN   4:00:00 PM EDT
122.41
+1.39 (+1.15%)
4:06:29 PM EDT: $122.28 -0.13 (-0.11%)
Products

Seagen Announces U.S. FDA Approval Of New Indication For Adcetris® For Children With Previously Untreated High Risk Hodgkin Lymphoma

Published: 11/10/2022 18:30 GMT
Seagen Inc (SGEN) - Seagen Announces U.S. FDA Approval of New Indication for Adcetris® (brentuximab Vedotin) for Children With Previously Untreated High Risk Hodgkin Lymphoma.
Seagen Inc - FDA Approval of New Indication for Adcetris Includes Boxed Warning for Progressive Multifocal Leukoencephalopathy.